



CODEN (USA): IAJPBB

ISSN: 2349-7750

**INDO AMERICAN JOURNAL OF  
PHARMACEUTICAL SCIENCES**<http://doi.org/10.5281/zenodo.258181>Available online at: <http://www.iajps.com>

Research Article

**FORMULATION AND EVALUATION OF MINOXIDIL  
EMULGEL FOR ANDROGENIC ALOPECIA**Usmania\*<sup>1</sup>, Ajay Bilandi<sup>2</sup>, Mahesh K. Kataria<sup>3</sup><sup>1</sup>Research Scholar, M.Pharm [Pharmaceutics], Sem IV, Seth G.L. Bihani S.D. College of Technical Education, Sri Ganganagar, Rajasthan, India.<sup>2</sup>Assistant Professor, Dept. of Pharmaceutics, Seth G.L. Bihani S.D. College of Technical Education, Sri Ganganagar, Rajasthan, India.<sup>3</sup>Professor and Head, Dept. of Pharmaceutics, Seth G.L. Bihani S.D. College of Technical Education, Sri Ganganagar, Rajasthan, India.**Abstract:**

*Androgenic alopecia is the loss of hair, pertains on the scalp although on other body sites. Alopecia is characterized by round or oval patches of non scarring hair loss. Scalp hair loss can be partial or complete, but it progress to cause total body hair loss. Emulgel are emulsion gel which contains widely distributed oil droplets. Chemically, minoxidil is 2,4-pyrimidinediamine, 6-[1-piperidinyl]-,3-oxide. Minoxidil is antihypertensive drug; a powerful vasodialator which act by direct relaxation of arteriolar smooth muscle. An attempt was made to formulate minoxidil emulgel for the treatment of male pattern baldness with the use of different gelling agents i.e. carbopol 940, carbopol 934, xanthan gum, methyl cellulose. Infra red [IR] spectroscopy was performed to identify any physicochemical interaction between drug and carriers. The dissolution profile and various evaluation parameters viz. pH, spreadability, viscosity, drug content, etc. of emulgel formulation and marketed formulation were compared. Release kinetics by various models were studied and compared between final formulation and marketed formulation. Thus, results showed no interactions between drug and polymers. Thus, minoxidil emulgel was found to be feasible over other dosage form in the treatment of androgenic alopecia.*

**Keywords:** *Androgenic alopecia, minoxidil, emulgel, FTIR, dissolution profiles.***Corresponding author:**

**Usmania,**  
Research Scholar, M.Pharm [Pharmaceutics], Sem IV,  
Seth G.L. Bihani S.D. College of Technical  
Education, Sri Ganganagar, Rajasthan, India.

QR code



Please cite this article in press as Usmania et al, *Formulation and Evaluation of Minoxidil Emulgel for Androgenic Alopecia*, Indo Am. J. P. Sci, 2016; 3(12).

## INTRODUCTION:


Androgenic alopecia is the loss of hair, pertains on the scalp although on other body sites. It is the common problem of the society which causes economical and physiological consequences. [16] alopecia is generally of two types i.e. alopecia areata and androgenic alopecia. Alopecia areata is characterized by round or oval patches of non scarring hair loss. Scalp hair loss can be partial [transient or persistent] or complete [alopecia totalis], but it progress to cause total body hair loss [alopecia universalis]. [13]

Transdermal drug delivery system provides sustain drug release as well as reduce the intensity of action and side effects of oral therapy. It delivers the drug across the skin by the process of diffusion and have an effect on the tissue adjacent to the site of application [topical] or to have an effect after through the circulatory system [systemic]. It bypasses the gastrointestinal tract and obviates the GI irritation that would occur frequently. [2].

Emulgel are emulsion gel which contains widely distributed oil droplets. They are generally emulsions either of oil-in-water or water-in-oil type, which are gelled by mixing with gelling agent. Minoxidil emulgel was applied topically and was shown to improve blood flow in human balding skin.

Chemically, minoxidil is 2,4-pyrimidinediamine, 6-[1-piperidinyl]-,3-oxide. Minoxidil is antihypertensive drug; a powerful vasodilator which act by direct relaxation of arteriolar smooth muscle. [6] Tachycardia, palpitations, angina and edema are observed when doses of  $\beta$ -blockers and diuretics are inadequate. Headache, sweating, and hirsutism, which is particularly bothersome in women are relatively common. [8].

### Chemical Structure of Minoxidil



[1]

**Fig 1: Structure of Minoxidil**

## MATERIALS AND METHODS:

Minoxidil was kindly provided by ONS pharmaceuticals pvt ltd, Jaipur, carbopol 940 and sodium hydroxide from Lobi chem, mumbai; carbopol 934 and methyl cellulose from molychem,

HPMC from Alembic pharmaceuticals ltd, vadodara, Xanthan gum from Vinubhai agencies pvt ltd, Potassium dihydrogen-ortho-phosphate and hydrochloric acid from Central drug House pvt ltd, New Delhi.. All chemical and reagents used were of analytical grade. De-ionized water was used for the complete study.

### Preformulation Studies

Preformulation studies are required to ensure the development of a stable as well as therapeutically effective and safe dosage form. These studies focus on the physicochemical properties of the drug that could affect performance and development of an efficacious dosage form.

### Description of drug

Organoleptic properties of drug i.e. color, odor, hygroscopicity, solubility was observed.

### Drug Identification

#### UV spectrophotometric analysis of drug

UV absorption in the range 200 to 400 nm of a 2mg/ml solution in water was determined. [19].

#### Fourier Transform Infra Red analysis of drug

FTIR spectrum of the drug was taken and compared with the reference spectrum to identify the drug. Accurately weighed quantity of minoxidil was placed in vial and kept at 50°C for 15 days. The sample was placed in ATR based Brukers Tensor 27 instrument.

#### Drug excipient compatibility study

Drug and different polymers alone and together were taken to study the interaction between them under certain experimental conditions. They were taken in ratio 1:1 ratio and were kept at 50°C for 15 days. [17].

#### Solubility determination:-

For quantitative solubility studies, known amount of drug [10mg] was suspended in a series of different solvents i.e. water, ethanol, propylene glycol and chloroform and shaken for 24 hrs. using wrist action shaker [York India]. Solubility of minoxidil in different solvents is recorded. [11].

#### Melting point determination:-

Melting point determination of minoxidil is done by using Melting Point Apparatus. In that method the pre-sealed capillary is filled by the small amount of drug. Then capillary and thermometer were placed in Melting Point Apparatus. Then see capillary for melting the drug. The temperature were noted when the drug start to melt and the drug till complete melt. [18]

**Analytical estimation of drug****Determination of absorption maxima**

Stock solution of minoxidil was prepared by dissolving 50 mg of drug using water in 100 ml volumetric flask. This stock solution was further diluted in water to get standard solution of concentration 100 microgram per ml and was scanned between 200 – 400 nm using UV spectrophotometer [shimadzu 1700] [12]

**Standard curve of minoxidil**

Standard curve was prepared using phosphate buffer pH 7.4. 100mg of minoxidil was dissolved in 100 ml of PBS to give a solution of 1mg/ml i.e. 1000 µg/ml. thus served as first standard stock solution. From this stock solution 1 ml was taken and diluted to 100 ml using pH 7.4 phosphate buffers to get a solution of 10 µg/ml concentration and this solution served as the second standard solution. Into a series of 10 ml volumetric flasks, aliquots of second standard solution [i.e.] 2 ml, 4 ml, 6 ml, 8ml, 10ml and 12 ml was added and the volume made up to 10 ml using pH 7.4 phosphate buffer. The absorbance of these solutions was measured against reagent blank at 286 nm using Shimadzu [UV-1700] UV spectrophotometer. Standard curve was plotted with concentration on x-axis and absorbance on y-axis. [9]

**Formulation and Evaluation of Emulgel****Fabrication of minoxidil emulgel:**

Dissimilar formulations were formulated using altering amount of gelling agents. the method only

differed in the process of making gel in diverse formulations. The formulation of emulsion was same in all formulations. Total 20 formulations; four formulations with each polymer were formulated. Gel bases were prepared by dispersing carbopol 940, carbopol 934, HPMC, xanthan gum and methyl cellulose in the de-ionized water. These dispersions were kept overnight in refrigerator for complete swelling of the gelling agent. pH of all the gel formulations were adjusted to 6.0-6.5 using triethanolamine Oil phase and aqueous phases are prepared separately to formulate emulsion. Emulgels were prepared by equal mixing of gel and emulsion in ratio of 1:1 with gentle stirring.

**Formulation and Evaluation of Emulgel**

Sixteen formulations using four polymers i.e. Carbopol 940, Carbopol 934, Xanthan Gum, Methyl Cellulose of different concentration [1%, 1.5%, 2%, 2.5%] were formulated. HPMC was also the choice of polymer but due to poor viscosity it was not used for the study. Tables below show the formulae of different polymers with different ratio. F1 to F4 was formulated with carbopol 940, F5 to F8 was formulated with carbopol 934, F9 to F12 was formulated with xanthan gum, F13 to F16 was formulated with Methyl cellulose. F17 to F20 was formulation with HPMC but due to poor viscosity these four formulations were not carried for further study.

**Table 1: Formulation batches of minoxidil emulgel**

Formulation code/ Ingredient	F 1	F 2	F 3	F 4	F 5	F 6	F 7	F 8	F 9	F 10	F 11	F 12	F 13	F 14	F 15	F 16
<b>Minoxidil</b>	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1	1
<b>Polymer</b>	1	1.5	2	2.5	1	1.5	2	2.5	1	1.5	2	2.5	1	1.5	2	2.5
<b>Propylene glycol</b>	15	15	15	15	15	15	15	15	15	15	15	15	15	15	15	15
<b>Triethanol amine</b>	0.6	0.7	0.8	0.9	0.6	0.7	0.8	0.9	0.6	0.7	0.8	0.9	0.6	0.7	0.8	0.9
<b>Ethanol</b>	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5	5
<b>Propyl paraben</b>	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
<b>Span 80</b>	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12	12
<b>Liquid paraffin</b>	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25
<b>Distilled water</b>	qs	qs	qs	qs	qs	qs	qs	qs	qs	qs	qs	qs	qs	qs	qs	qs

### Selection of emulgel formulation

On the basis of various evaluation parameter viz. viscosity, spreadability and in vitro drug release study two formulations i.e. F3 and F5 were found to be optimum for the further study. These two formulations were analyzed again and were evaluated and one best formulation was selected i.e. F5. This final formulation was then reformulated and evaluated; and was compared with the available marketed preparation i.e. Tugain gel 5% by cipla for all evaluation parameters.

### Evaluation of emulgel:

Following parameters were used for the evaluation of emulgel

### Physicochemical characters

#### Homogeneity

All the formulations were inspected visually for the physical appearance and for the presence of aggregates.

#### pH

pH of all formulations was determined by using digital pH meter. One gram of the emulgel formulations was dissolved in 100 ml of distilled water for pH measurement in triplicate and average was taken.

#### Drug content study

All the formulations were dissolved in 50 ml of phosphate buffer pH7.4. The volumetric flasks were kept for 2 hr and shaken well in shaker to mix it properly. The solution was passed through the whatman filter paper and filtrates were analyzed for drug content spectrophotometrically at 286nm against corresponding gel concentration as blank

#### Viscosity

Viscosity of all the formulations were measured using Brookfield viscometer using spindle no 61, 63, 64.

#### Spreadability

The spreadability was determined by parallel plate method which is widely used for determined and quantifying the spreadability of semisolid preparations. Formulations [1gm] were passed between two 20\*20 cm horizontal plates, the upper of which weighed 125 gm. The spread diameter was measured after 1 min.

#### In Vitro Drug Release Study

The in vitro drug release studies were carried out using Franz Diffusion Cell. Weighed quantity of emulgel formulation was sandwiched between egg

membranes of donor compartment and receptor compartment of FD cell using phosphate buffer of pH 7.4 as dissolution media. Temperature of the cell was maintained at 37°C and was placed on magnetic stirrer. 1 ml of the sample was withdrawn at suitable time interval and sink conditions were maintained. Samples were analyzed spectrophotometrically at 286nm. [8,14]

#### Stability study

The stability study was carried out for the most satisfactory formulation. The most satisfactory formulation i.e. final formulation was packed in a collapsible tube was submitted to accelerated stability tests Doaa A. Helal, 2012]. The emulgel formulation was kept at 4° C and 40° C for 30 days for evaluation of color, odor, pH, viscosity, etc. [21].

#### Drug Release Kinetic

#### Statistical Method

##### ANOVA

Analysis of variance is the method based on repeated measures design where time is the repeated factor and percent dissolved is dependent variable. ANOVA for varying concentration for different polymer and all together are measured. ANOVA studies are done through Graph Pad Prism version 7.02. [5]

#### Model Independent Methods

A simple model independent approach uses a difference factor [f1] and a similarity factor [f2] to compare dissolution profiles. [3]

#### Difference Factor [f1]

It calculates the percent difference between the two curves at each time point. It is a measure of the relative error between the two curves. Formulae for calculating f1 is mentioned below:

$$f1 = \sum [R_t - T_t] / \sum R_t \times 100$$

#### Similarity Factor [f2]

The similarity factor is a logarithmic reciprocal square root transformation of the sum of squared error and is a measurement of the similarity in the percent dissolution between the two curves i.e. test and reference. It represents closeness of two comparative formulations. It is calculated by:

$$f_2 = 50 \times \log \left\{ \left[ 1 + \frac{1}{n} \sum_{t=1}^n (R_t - T_t)^2 \right]^{-5} \times 100 \right\}$$

[3, 15]

**Table 2: comparison of dissolution profiles [3]**

f1	f2	Inference
0	100	Dissolution profiles are identical
≤15	≥ 50	Similarity or equivalence of two profiles

**Model dependent methods**

Data obtained from in vitro release studies of minoxidil emulgel was fitted to various kinetic equation to know about the release mechanism of drug from the formulation compared to commercial products Model dependent approach includes zero order, first order, Higuchi, Korsmeyer – Peppas Model, etc. Quantitative as well as the qualitative changes in a formulation alter drug release and in vivo performances that facilitate the product development. In case of zero order, it follows  $Q_t = Q_0 + K_0t$  equation, the graph was plotted in log cumulative percent of drug released versus time. In case of first order, it follows  $\log C = \log C_0 - Kt/2.303$  equation, the graph was plotted in log cumulative percent of drug remaining versus time. In case of Higuchi model, it follows  $Q = K_H \times t^{1/2}$  equation, the graph was plotted between %cumulative drug release versus square root of time.

In case of Korsmeyer peppas model, it follows  $Q/Q_0 = Kt^n$  equation, the graph was plotted between cumulative percent drug release versus log time. [4,5, 20]

**RESULTS AND DISCUSSION:****Description of Drug**

Various properties of drug related with color, odor are given in table

**Table 2: Description of Drug**


S. No.	Properties	Inference
1.	Colour	White
2.	Odour	Odourless

**Identification of drug****By UV spectrophotometric analysis of drug:**

The wavelength at which maximum absorbance obtained was considered as maximum wavelength [ $\lambda_{max}$ ] i.e. 286 nm for the drug. [12]

**By FTIR spectrum method:**

The IR spectra indicates absorption peaks of minoxidil at  $3451\text{ cm}^{-1}$  due to N-H,  $3282\text{ cm}^{-1}$  due to H-bonded N-H,  $2926\text{ cm}^{-1}$  due to C-H stretch [aromatic and aliphatic],  $1723\text{ cm}^{-1}$  show the peak of C=N,  $1543\text{ cm}^{-1}$  shows the presence of aromatic C=C stretching and N-O stretching is observed at  $1223\text{ cm}^{-1}$ . Peaks obtained in spectrum of pure drug [immediate and after 15 days] were similar to the given in standard.

**Fig 2: Reference FTIR Spectrum of Minoxidil**




Fig 3: FTIR spectrum of minoxidil [immediate]




Fig 4: FTIR spectrum of minoxidil [after 15 days]

#### Drug excipient compatibility study

The possible interaction between drug and excipient were studied by IR spectroscopy. The peaks of drug

and polymer immediate and after 15 days at 50°C were compared to standard drug sample that occurs between drug and polymers.




Fig 5: FTIR spectrum of drug + carbopol 940 [immediate]




Fig 6: FTIR spectrum of drug + carbopol 940 [after 15 days]




Fig 7: FTIR spectrum of drug + carbopol 934 [immediate]




Fig 8: FTIR spectrum of drug + carbopol 934 [after 15 day]




Fig 9: FTIR spectrum of drug + xanthan gum [immediate]




Fig 10: FTIR spectrum of drug + xanthan gum [after 15 days]




Fig 11: FTIR spectrum of drug + HPMC [immediate].






Fig 12: FTIR spectrum of drug +HPMC [after 15 days].




Fig 13: FTIR Spectrum of drug + Methyl Cellulose [immediate].




Fig 14: FTIR spectrum of drug + Methyl cellulose [after 15 days]

Table 3: Quantity used for Drug and Polymer identification

S. No.	API and Excipients	Quantity per vial [mg]	No. of Vials		Results [complies or not]
			Initial	50°C	
				After 15 Days	
1	Minoxidil	10	1	1	Complies
2	Minoxidil and Carbopol 940	10	1	1	Complies
3	Minoxidil and Carbopol 934	10	1	1	Complies
4	Minoxidil and Methyl Cellulose	10	1	1	Complies
5	Minoxidil and Xanthan Gum	10	1	1	Complies
6	HPMC	10	1	1	Complies

**Analytical methods of estimation**

Analytical methods were developed for the analysis of minoxidil using UV Spectroscopy. This method obeyed Beer's law.

**Determination of absorption maxima [ $\lambda_{max}$ ]/wavelength maxima:**

Absorption maxima of minoxidil found to be 286 nm.

**Standard curve of minoxidil in phosphate buffer solution [pH 7.4]**

Calibration curve of minoxidil was obtained with phosphate buffer pH7.4. Calibration curve was drawn using different values of absorbance at their respective concentration mentioned below in a table 4.

Table 4: Standard calibration curve in phosphate buffer pH 7.4 at  $\lambda_{max}$  286 nm

Concentration [mcg/ml]	Absorbance 1 [nm]	Absorbance 2 [nm]	Absorbance 3 [nm]	Average
4	0.149	0.103	0.195	0.149
8	0.320	0.217	0.423	0.320
12	0.502	0.392	0.612	0.502
16	0.624	0.507	0.714	0.624
20	0.820	0.731	0.909	0.820
24	1.016	0.934	1.098	1.016




Fig 15: Calibration curve of minoxidil in PBS pH 7.4 at 286 nm

**Solubility determination**

Solubility of minoxidil was studied in different solvents. Minoxidil was soluble in water, readily soluble in ethanol or propylene glycol and insoluble in chloroform.

**Table 5: Solubility studies of Minoxidil**

S.No.	Solvent	Solubility Standard [mg/ml]	Solubility observed [mg/ml]
1	Water	2.0 - 2.5	2.04
2	Alcohol	29	23
3	Chloroform	0.5	0.3
4	Propylene Glycol	75	72.38

**Melting Point Determination**

Melting point of minoxidil was estimated using melting point apparatus and was found to be in the range of 223-225°C.

**Evaluation****Physicochemical properties**

The physicochemical properties viz. homogeneity, pH, viscosity, color were studied and are mentioned in table 6.

**Table 6: Physicochemical properties of all formulation**

Formulation code	Homogeneity	pH	Viscosity [cps]	Color
F1	Homogeneous	6.4	1970	White
F2	Homogeneous	6.3	4310	Off white
F3	Homogeneous	6.7	10570	White
F4	Homogeneous		10930	White
F5	Non homogeneous	6.2	79	White
F6	Homogeneous	6.5	142	White
F7	Homogeneous	6.5	427	White
F8	Homogeneous	6.6	924	Off white
F9	Homogeneous	6.3	1370	White
F10	Homogeneous	6.4	1458	White
F11	Homogeneous	6.7	1689	White
F12	Homogeneous	6.5	1783	White
F13	Homogeneous	6.4	34	White
F14	Homogeneous	6.5	72	White
F15	Homogeneous	6.5	221	White
F16	Homogeneous	6.4	294	White

**In vitro drug release**

In vitro drug release studies were carried out using Franz diffusion cell using phosphate buffer solution pH 7.4. The rate release profile was plotted as the percentage versus time thus showing drug release increases with increase in time. The dissolution profile is presented in table 7.

**Table 7: In vitro dissolution profiles of all formulations**

Formulation code	5 [min]	10 [min]	15 [min]	30 [min]	45 [min]	60 [min]
F1	40.2	45.8	52.24	74.08	77.4	89.2
F2	82.2	83.8	94.4	138.4	148.6	167.8
F3	25.6	28.8	37	60.6	77.6	91.4
F4	24	26.4	34.6	51.4	63.6	78.2
F5	29.2	35.8	43.4	55	73	90.4
F6	15.4	14.8	20.8	28.4	37.4	43
F7	10	11.6	14.6	18.8	24.8	33.2
F8	25.2	31.8	37.6	51.8	62.4	68.6
F9	33.2	37.6	41.2	54.6	67.6	75.2
F10	25.8	32.2	37.4	53.2	64.6	75.2
F11	24.6	30.4	36.6	45	58.2	67
F12	25.2	31.8	37.6	51.8	62.4	68.6
F13	36	46.8	55.2	75.8	87.6	91.8
F14	30	40.6	47	62.4	72.2	81.4
F15	29.4	35.4	43.6	57.2	68	76.2
F16	30.4	36.2	42.8	57.4	68	72

It was observed that the formulations F3 and F5 showed high release of drug.

**Physicochemical properties of selected formulation**

Physicochemical properties of two selected formulations with code F3 and F5 were studied and results are shown in table 8.

**In vitro drug release of selected formulation**

Percentage release of F3 was found to be 88.1% and that of F5 was 89.9%. Drug release profiles of both formulations are shown in table 9.

**Physicochemical properties of final formulation and marketed formulation**

F5 was found to be the better choice of formulation on the basis of various evaluation parameters viz. pH,

viscosity, in vitro drug release profile, etc. Physicochemical properties of final formulation and marketed formulation are enlisted in table 10.

**Drug content**

Drug content of the final formulation was found to be 99.04 and that of the marketed formulation 99.62.

**In vitro drug release study**

Release profiles of both i.e. final and marketed formulation were carried out using franz diffusion cell with phosphate buffer pH 7.4. Results are mentioned in table 11.

**Table 8: Physicochemical properties of selected formulations**

Formulation code	Homogeneity	pH	Viscosity [cps]	Color
F3	Homogeneous	6.4	84	White
F5	Homogeneous	6.7	11236	White

**Table 9: In Vitro dissolution profile of selected formulations**

Formulation code	5 [min]	10 [min]	15 [min]	30 [min]	45 [min]	60 [min]
F3	25.4	32.6	38.3	59.7	73.4	88.1
F5	30.1	36.5	47.3	62.4	77.6	89.9

**Table10: Physicochemical properties of final formulation and marketed formulation**


Formulation code	Homogeneity	pH	Viscosity [cps]	Color	Spreadability [gm*cm/sec]
Final formulation	Good	6.74	10513	White	208.55
Marketed formulation	Good	6.85	931	Pale yellow	190.14

**Table 11: Dissolution profiles of final formulation and commercial formulation**

Formulation code	5 [min]	10 [min]	15 [min]	30 [min]	45 [min]	60 [min]
Final formulation	26.4	29.4	38.2	58.4	84	90.6
Marketed formulation	36.54	40.14	41.68	77.36	86.9	102.06

**Drug release profiles of final and marketed formulation**

[red line indicates drug release profile of marketed formulation and blue line indicates drug release profile of final formulation]



**Fig 16: Drug release of marketed formulation**

#### Stability study of Final formulation

Stability study for the final emulgel formulation was carried out at 4°C and 40°C for one month and no

significant changes were observed. Thus results are enlisted in table mentioned below.

**Table 12: Stability study**

Parameters	Initial	At 4°C		At 40°C	
		After 15 days	After 30 days	After 15 days	After 30 days
Color	White	White	White	White	White
pH	6.74	6.71	6.9	6.6	6.4
Viscosity [cps]	10513	10761	10106	10839	11041
Spreadability [gm*cm/sec]	208.55	207.91	206.85	207.63	206.01
% Drug release	90.6	90.1	89.3	89.8	89.1

#### Kinetic Modelling, Statistical Methods


##### ANOVA

The results found to be significant except for Carbopol 934 and are concluded in the table 13 and graph of all polymers together is shown in fig 17.

**Table 13: p Values of all polymers**

Polymer	p value	Result
Carbopol 940	0.0001	Significant
Xanthan gum	0.0003	Significant
Carbopol 934	0.0659	Not significant
Methyl Cellulose	0.0005	Significant
All polymers together	0.0010	Significant

#### Repeated measures one-way ANOVA data



**Fig 17: ANOVA Graph for all polymers together**

**Table 14: Calculation of similarity factor and difference factor**

S.No.	Time [min]	Test	Reference	Reference - Test	$\sum[R_i - T_i]^2$	f2 Difference Factor	f1 Similarity Factor
1	5	26.4	36.54	10.14	102.81	51.01	14.99
2	10	29.4	40.14	10.74	115.34		
3	15	38.2	41.68	3.48	12.11		
4	30	58.4	77.36	18.96	359.48		
5	45	84	86.9	2.9	8.41		
6	60	90.6	102.06	11.46	131.331		

**Model Independent Methods**

A simple model independent approach uses a difference factor [f1] and a similarity factor [f2] to compare dissolution profiles.

**Difference Factor [f1] and Similarity factor [f2]**

The similarity and difference factor obtained for minoxidil emulgel was found to be within the standard. f1 should be less than 15 and the results were found to be 14.99. There was no significant variation in the in vitro drug release profile of commercial product and final preparation. f2 should be more than 50. The result was found to be 51.01

thus indicates the similarity between dissolution profiles of both.

**Model dependent Methods**


The release of formulation F5 was indicated by highest  $r^2$  values in zero order model which is similar to that of the commercial product i.e. highest  $r^2$  value was seen in zero order model thus showed the release mechanism as Non-Fickian. Table 15 summarized the correlation coefficients for different release kinetics model of minoxidil emulgel and commercial formulation.

**Table 15:  $R^2$  values of different models for final formulation and marketed formulation**

Formulation	Model	$R^2$ value
Final	Zero order	0.977
	First order	0.958
	Higuchi equation	0.972
	Korsmeyer Peppas	0.96
Marketed	Zero order	0.959
	First order	0.930
	Higuchi equation	0.957
	Korsmeyer	0.767

**A. Final Formulation**

- Zero order equation

**Fig 18: Zero order equation of Final Formulation**

- First order equation




Fig 19: First order equation of Final Formulation

- Higuchi equation




Fig 20: Higuchi equation of Final Formulation

- Korsmeyer peppas equation




Fig 21: Korsmeyer peppas equation of Final Formulation

### 1. Marketed formulation

- Zero order equation




Fig 22: Zero order equation of Marketed Formulation

- First order equation




Fig 23: First order equation of Marketed Formulation

- Higuchi equation





Fig 24: Higuchi equation of Marketed Formulation



- **Korsmeyer peppas equation**



**Fig 25: Korsmeyer Peppas equation of Marketed Formulation**

### CONCLUSION:

This research was carried out to develop minoxidil emulgel with aim to deliver the drug to systemic circulation through skin thus avoid first pass metabolism, improves stability and enhance residence time. Sixteen formulations were formulated and F5 was the one best out of all. Comparative study was done with the available minoxidil topical commercial preparation i.e. Tugain gel 5%. Thus minoxidil were found to be feasible over minoxidil gel as application of marketed formulation produces burning sensation [due to presence of high content of alcohol] but the emulgel formulation does not produce any burning sensation along with good spreadability Hence minoxidil emulgels were found to be effective for treating androgenic alopecia.

### ACKNOWLEDGEMENT:

The author takes privilege to express special gratitude to Management, Seth G.L. Bihani S.D. college of Technical Education, Sri Ganganagr for providing the facilities of laboratory and chemicals for conduct of the research work. I would also like to thank ONS Pharmaceuticals pvt. ltd., Jaipur for providing ex gratis sample of minoxidil; Lobi Chem, Mumbai for carbopol 940 and sodium hydroxide pellets; Vinubhai agencies pvt ltd, Mumbai for providing Xanthan gum; Central drug house pvt. ltd, for providing potassium dihydrogen phosphate and hydrochloric acid; HPMC for Alembic pharmaceutical ltd, Vadodara for conduct of the research work.

### Conflict of Interest:

No conflict of interest

### REFERENCES:

1. Anthony C Maffot, M. David Osselton. Brian Widdop. Clarkes Analysis of drug and Poison in

Pharmaceutical Body Fluid and Postmortem Material. London Pharmaceutical Press. Electric Version. 3<sup>rd</sup> edition Volume I.

2. Bhowmik Debjit, Chiranjib, Chandira Maergret, Jayakar. B, Sampath K.P. Recent advances in Transdermal Drug Delivery System. A Research Article. International Journal of PharmTech Research. 2010. 2 [1]. 68-77.

3. Brahmankar, D.M Jaiswal, S.B. Bio-pharmaceutics and Pharmacokinetics A Treatise. 2<sup>nd</sup> edition. Vallabh Prakashan. Delhi. 2009. 331

4. Costa P & Jose MSL, Modeling and comparison of dissolution profiles, Eur J Pharm Sci, 13, 2001, 123-133.

5. Costa Paulo, Lobo Sousa Manuel Jose. Modeling and comparison of dissolution profiles. A Review Article. European Journal of Pharmaceutical Science. 2001. 13. 123-133.

6. European Pharmacopoeia. Council of Europe, Strasbourg. 5 edition. [5.1]. 2004. 2974.

7. Florey Klaus. Analytical Profiles of Drug Substances. Volume 17. 185-220.

8. FM Sakr, et al. Preparation and evaluation of a multimodal minoxidil microemulsion versus minoxidil alone in the treatment of androgenic alopecia of minoxidil etiology: a pilot study. A research article. NCBI. 2013. [7]. 413-423.

9. G Vijayamma, P Salomi, P Venkatesh, D Rani Kala Hepcy, A Gowramma, P Mounika. Analytical Method Development and Validation of Minoxidil in Pharmaceutical Dosage Form by UV Spectrophotometry. A Research article. International Journal of Innovative Pharmaceutical Research. 2015. 6[1]. 464-467.

10. George Eby and Mathews Manju Maria. Formulation and Evaluation of Topical Gel containing Hair Growth Promoters for the Treatment of Androgenic Alopecia. A Research Article. 2014. 4[1]. 1-8.

11. Helal Doaa, Rhman Dalia Abdel, Halim Abdel, Nabarawi Mohamed A. El. Formulation and Evaluation of Fluconazole Topical Gel. A research article. *Intrnational Journal of Pharmacy and Pharmaceutical Sciences*. 2012. 4[5]. 175-183.
12. Patel PD, Suruti NI, Upadhyay UM. Development and Validation of Stability Indicating Methods for Minoxidil and Finestrine in its Pharmaceutical Dosage Forms. *International Journal for Pharmaceutical Research Scholars*. 2015. 4[1], 221-238.
13. Rabinarayan Parhi, Bhaskara Rao Terapalli, Teja B.B. Formulation and In Vitro Evaluation of Minoxidil Topical Gel. A Research Article. *Turk J Pharm Sci*. 2014. 11 [2]. 153-162.
14. Sampathi Sunitha, Wankar Jitendra, Dodoala Sujatha, Mankala Santhosh Kumar. Design and Evaluation of Hydrogel Thickened Microemulsion for Topical Delivery of Minoxidil. *Iranian Journal of pharmaceutical Sciences*. 2013. 9 [4]. 1-14.
15. Shaikh Kauser Hina, Kshirsagar R.V, Patil G.S. Mathematical Models for Drug Release Characterization: A Review. *World Journal of Pharmacy and Pharmaceutical Sciences*. 2015. 4 [4]. 324-338.
16. Shatalebi M.A, Rafiei.Y. Preparation and evaluation of Minoxidil Foamable Emu Oil Emulsion. A Research Article. *Research in Pharmaceutical Sciences*. 2014. 9 [2]. 123-133.
17. Silverstein RM, Bassler GC. Spectrometric Identification of Organic Compounds. *Chem. Educ*. 1<sup>st</sup> ed. 1963. 71-109.
18. The United state Pharmacopoeia, The National Formulary. United states Pharmacopial Convention Inc. Rockville, 2005, 1300.
19. Zahid A Zaheer, Shahed Mirza, Ismail Moazzam and Imraan W Sayad. UV-Spectrophotometric Determination of Minoxidil and Its Application to the Assay in Pharmaceutical Dosage Forms. A Research Article. *Der Pharma Chemica*. 2012. 4[1]. 568-573.
20. Dash S., Murthy P.N., Nath Lilakanta, Chowdhury P. Kinetic Modeling on Drug Release from Controlled Drug Delivery Systems. *Acta Poloniate Pharmaceutical Drug Research*. 2010. 67 [3]. 217-223.
21. Gabriel Milla, Dantas Belarmino, Goncalves Alan Silvio, et al. Development and Evaluation of gel Formulation Containing the Monoterpene Borneol. *The Scientific World Journal*. 2016.